Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5%) completed the induction cycle and 215 (52.3%) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1%) and 60 (14.6%) patients. Ninety-three patients (30.2%) stopped BCG, 9 (9.7%) for recurrence and 14 (15.1%) for grade-3 toxicity. Intriguingly, 55 (59.1%) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60% of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.

Journal Section:
Editor's choice
Keywords:
Non-muscle invasive bladder cancer, Intravesical instillation, Immunotherapy, Compliance, Toxicity, Bacillus Calmette Guèrin
1.
Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
[PubMed]
https://doi.org/10.1097/00005392-200211000-00016
2.
Malmström PU, Sylvester RJ, Crawford DE, et al: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-256.
[PubMed]
https://doi.org/10.1016/j.eururo.2009.04.038
3.
Oddens J, Brausi M, Sylvester R, et al: Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-472.
[PubMed]
https://doi.org/10.1016/j.eururo.2012.10.039
4.
Babjuk M, Burger M, Zigeuner R, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-653.
[PubMed]
https://doi.org/10.1016/j.eururo.2013.06.003
5.
Witjes JA, Palou J, Soloway M, et al: Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742-750.
[PubMed]
https://doi.org/10.1111/bju.12012
6.
Clark PE, Agarwal N, Biagioli MC, et al; National Comprehensive Cancer Network (NCCN): Bladder cancer. J Natl Compr Canc Netw 2013;11:446-475.
[PubMed]
7.
Koya MP, Simon MA, Soloway MS: Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175:2004-2010.
[PubMed]
https://doi.org/10.1016/S0022-5347(06)00264-3
8.
Sylvester RJ, Brausi MA, Kirkels WJ, et al: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-773.
[PubMed]
https://doi.org/10.1016/j.eururo.2009.12.024
9.
Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest oncology group study. J Urol 2000;163:1124-1129.
[PubMed]
https://doi.org/10.1097/00005392-200004000-00014
10.
Van der Meijden AP, Sylvester RJ, Oosterlinck W, et al: Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial. Eur Urol 2003;44:429-434.
[PubMed]
https://doi.org/10.1016/S0302-2838(03)00357-9
11.
Brausi M, Oddens J, Sylvester R, et al: Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69-76.
[PubMed]
https://doi.org/10.1016/j.eururo.2013.07.021
12.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group: The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial. Eur Urol 2003;44:423-428.
[PubMed]
https://doi.org/10.1016/S0302-2838(03)00371-3
13.
O'Donnell MA: Optimizing BCG therapy. Urol Oncol 2009;27:325-328.
[PubMed]
https://doi.org/10.1016/j.urolonc.2008.10.024
14.
Rischmann P: Improving compliance of BCG immunotherapy: practical approaches to managing side-effects. Eur Urol Suppl 2006;5:660-661.
https://doi.org/10.1016/j.eursup.2006.05.004
15.
Porena M, Del Zingaro M, Lazzeri M, et al: Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 2010;84:23-27.
[PubMed]
https://doi.org/10.1159/000273461
16.
Oderda M, Ricceri F, Pisano F, et al: Prognostic factors including Ki-67 and p53 in bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study. Urol Int 2013;90:184-190.
[PubMed]
https://doi.org/10.1159/000343431
17.
Witjes JA: Maintenance bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: do we finally know the best schedule? Eur Urol 2013;63:473-474.
[PubMed]
https://doi.org/10.1016/j.eururo.2012.11.023
18.
Ehdaie B, Sylvester R, Herr HW: Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-585.
[PubMed]
https://doi.org/10.1016/j.eururo.2013.05.027
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.